COMMUNIQUÉS West-GlobeNewswire
-
Immutrin raises £65 million ($87 million) Series A to develop next generation antibody therapy for ATTR amyloidosis
24/03/2026 -
San Juan Regional Medical Center Selects Full PerfectServe Platform for Enterprise Communication and Scheduling Overhaul
24/03/2026 -
Privia Health Earns 2026 HFMA MAP Award for Revenue Cycle Excellence
24/03/2026 -
TOMI Environmental Solutions Disrupts the Dairy Industry with Major Mexican Dairy Brand
24/03/2026 -
Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
24/03/2026 -
Costa Rica Achieves Historic First With Nation’s Inaugural Export of GACP-Certified Medical Cannabis to the European Union
24/03/2026 -
IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026
24/03/2026 -
Sapu Nano to Launch Deciparticle™ Platform and Present Clinical Pipeline at BIO-Europe Spring 2026
24/03/2026 -
Leapfrog Bio Appoints Alan Ashworth, Ph.D., FRS, to Chair Company’s Scientific Advisory Board
24/03/2026 -
SK pharmteco and Prozomix Announce Strategic Collaboration to Enhance Biocatalysis Capabilities for Global Drug Manufacturing
24/03/2026 -
SurvivorRx Expands Personalized Supplement Routines as Oncologists Raise Concerns About Supplement Safety for Cancer Survivors
24/03/2026 -
CenTrak Advances Its RTLS Platform Through Enhanced Healthcare Integrations
24/03/2026 -
Press Release Biocartis NV: Biocartis to Collaborate with Medical College of Wisconsin on Breast Cancer Gene Signatures
24/03/2026 -
BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer
24/03/2026 -
Philips remains No. 1 in Medtech at European Patent Office and the largest Dutch patent applicant
24/03/2026 -
Transactions in connection with share buy-back program
24/03/2026 -
Zymeworks Announces Participation in Upcoming Investor Conferences
24/03/2026 -
iDEL Therapeutics Appoints Claudia Ulbrich as Chair of its Board of Directors
24/03/2026 -
AtaiBeckley Joins $3 Trillion CRSP Index and S&P Benchmark Indices Adding Mandatory Passive Fund Ownership to Phase 3 Pipeline Catalyst
24/03/2026
Pages